Open AccessAlbumin-bound paclitaxel as new treatment for metastatic cholangiocarcinoma: A case report
Author(s) -
R. Martín Huertas,
Raquel Fuentes-Mateos,
Juan José Serrano Domingo,
E. Corral de la Fuente,
Mercedes Rodríguez-Garrote
Publication year - 2020
Publication title -
world journal of clinical oncology
Language(s) - English
Resource type - Journals
ISSN - 2218-4333
DOI - 10.5306/wjco.v11.i10.844
Subject(s) - medicine , gemcitabine , oncology , taxane , paclitaxel , folfox , capecitabine , chemotherapy , pancreatic cancer , gastroenterology , cancer , surgery , breast cancer , oxaliplatin , colorectal cancer
Cholangiocarcinomas are rare and very aggressive tumors. Most patients have advanced-stage or unresectable disease at presentation, and the systemic therapies have limited efficacy. Albumin-bound paclitaxel (nab-paclitaxel) is a solvent-free taxane that has been approved for the treatment of some cancers such as breast, non-small cell lung and pancreatic cancer, however it has not been applied to treat cholangiocarcinoma. We have both preclinical and clinical evidence of the efficacy of nab-paclitaxel in cholangiocarcinoma, yet no phase 3 trials have been made.